hospitals in 14 countries across four continents are participating in the study. The objective is to collect data from patients that are representative of those seen in everyday clinical practice in contrast to the narrowly defined population of patients included in randomized clinical trials. The goals of GRACE are to:
• describe the diagnostic and treatment strategies for ACS patients seen in everyday practice
• describe in-hospital and long-term outcomes
• improve the quality of care for ACS patients
• develop hypotheses for future clinical research Each of the 94 study sites enrols 10 consecutive patients aged at least 18 years and who meet the eligibility criteria for GRACE (Table 1) • anti-ischemic therapy (e.g., nitrates, beta-adrenergic blockers and oxygen)
• antiplatelet therapy (e.g., aspirin and a GP IIb/IIIa receptor antagonist)
• anticoagulation (e.g., LMWH, UFH)
• invasive reperfusion strategy (e.g., PCI, either immediate or within 24 hours)
In patients with NSTEMI/UA, 87% did not receive a GP IIb/IIIa receptor antagonist. Additionally, only 12% received a GP antagonist before, during or after PCI. The guidelines state that these agents are effective in reducing event rates in the acute phase of treatment and this effect is enhanced in the setting of a PCI. 12 The GRACE data indicate that the majority of NSTEMI/UA patients undergo an early conservative strategy, with just over one-fifth undergoing PCI. By contrast, antithrombotic agents were used frequently in NSTEMI/UA, with only 16% failing to receive either UFH or LMWH.
Findings from GRACE -STEMI
Patients who present with STEMI should receive oxygen, nitroglycerin and analgesia, along with aspirin and a betaadrenergic blocking agent. In addition, they should be considered for thrombolytic therapy alone, primary PCI (with or without a stent), thrombolysis plus PCI, and emergency CABG.
Almost 30% of patients did not receive any form of reperfusion therapy. This may be because of contraindications to thrombolysis, no access to a catheterization laboratory, and difficulty with the diagnosis. Nevertheless, this finding indicates considerable room for improvement in the treatment of these patients. In this study, 31% of patients received thrombolytic therapy compared with 25% who underwent PCI. Fifteen percent received both a thrombolytic and underwent a PCI.
The majority of patients who had a PCI had a stent inserted (88%). Of those who underwent a primary PCI, 59% also received a GP IIb/IIIa antagonist, which dropped to 41% in patients who had a facilitated PCI. Antithrombotic therapy was given to 84% of patients undergoing a primary PCI, of whom 38% received UFH and only 15% LMWH. This finding is in spite of the advantages of enoxaparin over UFH. 13 Just over 30% of patients who had a PCI received both LMWH and UFH.
